r
espiratori
virus
caus
signific
morbid
mortal
worldwid
usual
clinic
manifest
describ
symptomatolog
common
cold
although
diseas
caus
virus
usual
trivial
last
day
virus
caus
diseas
sever
time
fatal
common
respiratori
virus
includ
influenza
parainfluenza
virus
respiratori
syncyti
viru
rsv
adenoviru
rhinoviru
review
describ
sever
viral
infect
caus
variou
respiratori
virus
specif
entiti
childhood
respiratori
infect
upper
airway
lower
airway
lung
parenchyma
describ
epidemiolog
data
respiratori
viral
infect
avail
mani
nation
mani
factor
studi
predict
outcom
guid
nation
polici
manag
infect
respiratori
viral
infect
caus
signific
morbid
miseri
affect
million
children
annual
worldwid
although
infect
shortliv
manag
gener
practition
children
serious
affect
requir
hospit
virus
account
larg
workload
mani
pediatr
depart
respons
upper
respiratori
infect
croup
bronchiol
pneumonia
studi
nearli
pediatr
admiss
commonest
childhood
hospit
admiss
associ
respiratori
viral
infect
chiu
colleagu
also
describ
influenza
infect
commonest
assess
diseas
burden
respiratori
disord
hong
kong
children
hospit
discharg
data
link
laboratori
data
nelson
colleagu
found
primari
diagnosi
respiratori
disord
common
upper
respiratori
tonsillitispharyng
crouplaryng
acut
otiti
media
bronchitischest
infect
bronchiol
pneumonia
influenza
asthma
allerg
rhiniti
recent
studi
viral
atyp
bacteri
pathogen
children
hospit
acut
respiratori
infect
identifi
use
broadcaptur
rapid
sensit
method
multiplex
polymeras
chain
reaction
pcr
assay
detect
differ
respiratori
pathogen
respiratori
specimen
children
hospit
period
acut
respiratori
tract
infect
includ
influenza
subtyp
influenza
b
parainfluenza
type
rsv
group
b
adenovirus
human
rhinovirus
enterovirus
human
metapneumovirus
human
coronavirus
sarscov
chlamydophila
pneumonia
legionella
pneumophila
mycoplasma
pneumonia
overal
posit
rate
time
higher
previou
report
base
convent
method
influenza
parainfluenza
rsv
account
noncultiv
virus
account
posit
case
influenza
peak
march
june
influenza
b
detect
januari
februari
april
parainfluenza
preval
throughout
year
except
april
june
rsv
infect
found
februari
septemb
adenoviru
multipl
peak
wherea
rhinoviru
coronaviru
detect
mainli
winter
earli
spring
rsv
infect
associ
bronchiol
parainfluenza
associ
croup
otherwis
clinic
manifest
larg
nonspecif
gener
children
infect
influenza
adenoviru
mix
virus
higher
temperatur
view
increas
concern
unexpect
outbreak
sever
viral
infect
rapid
multiplex
pcr
assay
valuabl
tool
enhanc
manag
hospit
patient
surveil
viral
infect
circul
commun
among
hospit
admiss
small
percentag
children
would
requir
pediatr
intens
care
unit
picu
support
hon
colleagu
report
clinic
pattern
outcom
children
laboratoryproven
diagnosi
respiratori
viru
infect
admit
picu
teach
hospit
three
respiratori
viru
speci
rsv
n
influenza
n
parainfluenza
n
account
case
picu
admiss
due
influenza
common
influenza
b
wherea
parainfluenza
type
commonest
subtyp
parainfluenza
infect
compar
common
virus
mean
age
children
admit
rsv
lower
influenza
parainfluenza
preexist
condit
prematur
chronic
lung
diseas
present
children
rsv
infect
respiratori
virus
caus
upper
croup
lower
respiratori
tract
diseas
bronchiol
pneumonia
extrapulmonari
present
less
preval
includ
enceph
seizur
cardiac
arrest
coexist
diabet
ketoacidosi
acut
lymphoblast
leukemia
one
patient
rsv
anoth
influenza
die
picu
stay
nearli
half
patient
requir
ventilatori
support
receiv
system
corticosteroid
receiv
initi
broadspectrum
antibiot
coverag
approxim
nebul
adrenalin
airway
endoscopi
bacteri
coinfect
adenoviru
isol
patient
adenoviru
type
die
picu
stay
similar
find
picu
report
particular
influenza
infect
caus
signific
morbid
mortal
young
children
immun
recommend
children
age
month
year
although
sever
form
influenza
rare
children
diseas
may
lifethreaten
occur
children
underli
diseas
influenza
season
increas
number
children
influenza
infect
admit
australian
picu
increas
number
death
compar
previou
year
cost
influenzarel
hospit
children
high
unit
state
studi
highrisk
patient
higher
mean
total
cost
lowrisk
patient
cardiac
metabol
neurologicneuromuscular
diseas
age
year
independ
associ
highest
hospit
cost
influenza
virus
rna
virus
famili
orthomyxovirida
influenzaviru
influenzaviru
b
influenzaviru
c
genera
affect
human
influenzaviru
one
speci
influenza
viru
type
virus
virul
human
pathogen
among
influenza
type
caus
sever
diseas
influenza
viru
differ
serotyp
base
antibodi
respons
virus
influenzaviru
b
also
one
speci
viru
almost
exclus
infect
human
less
common
influenza
viru
mutat
lower
rate
type
consequ
less
genet
divers
one
influenza
b
serotyp
reduc
rate
antigen
chang
combin
limit
host
rang
ensur
pandem
influenza
b
occur
influenzaviru
c
one
speci
influenza
c
viru
caus
mild
diseas
children
inde
seroepidemiolog
studi
reveal
influenza
c
viru
wide
distribut
global
nevertheless
isol
viru
difficult
report
clinic
featur
sever
ill
local
epidem
influenza
c
report
hay
colleagu
summar
evolut
influenza
virus
result
recurr
annual
epidem
diseas
caus
progress
antigen
drift
influenza
b
virus
due
mutabl
rna
genom
infrequ
sever
pandem
caus
emerg
novel
influenza
subtyp
popul
littl
immun
latter
characterist
consequ
wide
antigen
divers
peculiar
host
rang
influenza
virus
abil
segment
rna
genom
undergo
frequent
genet
reassort
recombin
mix
infect
contrast
featur
evolut
recent
circul
influenza
b
virus
includ
rapid
drift
virus
singl
lineag
slow
replac
success
antigen
variant
virus
cocircul
year
antigen
genet
distinct
lineag
influenza
b
virus
constant
monitor
chang
circul
virus
import
maintain
efficaci
influenza
vaccin
combat
diseas
diagnosi
influenza
base
clinic
impress
problemat
prospect
studi
children
year
old
younger
respiratori
infect
examin
visit
nasal
swab
specimen
obtain
detect
influenza
physician
record
opinion
whether
child
influenza
among
infect
overal
sensit
clinic
diagnosi
influenza
posit
predict
valu
transmiss
influenza
mathemat
model
help
predict
viru
spread
popul
peopl
contract
influenza
infecti
second
third
day
infect
infect
last
around
day
children
much
infecti
adult
shed
viru
develop
symptom
week
infect
influenza
control
import
investig
viral
shed
resist
virus
accord
mitamura
colleagu
viral
load
decreas
start
antivir
agent
resist
virus
detect
patient
influenza
spread
direct
transmiss
infect
person
sneez
mucu
eye
nose
mouth
anoth
person
peopl
inhal
aerosol
produc
infect
peopl
cough
sneez
spit
handtomouth
transmiss
contamin
surfac
direct
person
contact
rel
import
airborn
droplet
contact
transmiss
influenza
viru
effici
control
measur
depend
inactiv
virus
differ
environment
media
weber
colleagu
systemat
review
inform
environment
inactiv
influenza
virus
mode
transmiss
airborn
rout
potenti
import
transmiss
pathway
influenza
indoor
environ
import
droplet
transmiss
reassess
contact
transmiss
limit
fast
inactiv
influenza
viru
hand
depend
behavior
paramet
airborn
transmiss
howev
potenti
larg
inocula
deposit
environ
sneez
protect
effect
nasal
mucu
viru
surviv
could
make
contact
transmiss
key
transmiss
mode
airborn
rout
demonstr
inhal
one
inhal
droplet
lm
diamet
might
enough
caus
infect
although
singl
sneez
releas
droplet
droplet
larg
quickli
settl
air
influenza
viru
also
transmit
contamin
surfac
success
control
viral
diseas
requir
knowledg
differ
vector
could
promot
transmiss
among
host
thoma
colleagu
assess
surviv
human
influenza
virus
banknot
given
billion
note
exchang
daili
worldwid
banknot
experiment
contamin
repres
influenza
viru
subtyp
variou
concentr
surviv
test
differ
time
period
influenza
virus
test
cell
cultur
surviv
day
inocul
high
concentr
inoculum
presenc
respiratori
mucu
show
strike
increas
surviv
time
day
bhong
viru
still
infecti
day
mix
respiratori
mucu
nasopharyng
secret
natur
infect
children
use
influenza
viru
surviv
least
h
onethird
case
investig
conclud
unexpect
stabil
influenza
viru
nonbiolog
environ
suggest
unusu
environment
contamin
consid
set
pandem
prepared
bean
colleagu
investig
transmiss
influenza
virus
via
hand
environment
surfac
surviv
laboratorygrown
influenza
influenza
b
virus
variou
surfac
studi
influenza
b
virus
surviv
hour
hard
nonpor
surfac
stainless
steel
plastic
surviv
less
hour
cloth
paper
tissu
measur
quantiti
influenza
viru
transfer
stainless
steel
surfac
hand
hour
tissu
hand
minut
viru
surviv
hand
minut
transfer
environment
surfac
observ
suggest
transmiss
viru
donor
shed
larg
amount
could
occur
hour
via
stainless
steel
surfac
minut
via
paper
tissu
investig
conclud
transmiss
influenza
viru
via
fomit
may
possibl
condit
heavi
environment
contamin
howev
viru
present
mucu
viru
surviv
longer
period
new
influenza
virus
constantli
evolv
mutat
reassort
definit
mean
prophylaxi
vaccin
particular
highrisk
patient
may
develop
lifethreaten
primari
viral
pneumonia
complic
bacteri
pneumonia
vaccin
influenza
influenza
vaccin
recommend
children
month
year
old
due
high
mutat
rate
viru
particular
influenza
vaccin
usual
confer
protect
year
world
health
organ
annual
predict
viral
strain
like
circul
next
year
allow
pharmaceut
compani
develop
vaccin
provid
best
immun
strain
vaccin
reformul
season
specif
flu
strain
henc
possibl
vaccin
still
get
influenza
influenza
pandem
benefit
vaccin
antivir
medic
often
constrain
limit
suppli
effect
nonpharmaceut
public
health
intervent
vital
curtail
diseas
spread
good
person
health
hygien
habit
hand
wash
avoid
spit
cover
nose
mouth
sneez
cough
reason
effect
reduc
influenza
transmiss
particular
hand
wash
soap
water
alcoholbas
hand
rub
effect
inactiv
influenza
virus
simpl
person
hygien
precaut
recommend
main
way
reduc
infect
pandem
surfac
sanit
may
also
help
prevent
influenza
respiratori
viral
infect
alcohol
effect
sanit
influenza
virus
quaternari
ammonium
compound
also
use
alcohol
sanit
effect
last
longer
wide
varieti
activ
chemic
agent
biocid
found
sanit
product
mani
use
hundr
year
includ
alcohol
phenol
iodin
chlorin
hospit
quaternari
ammonium
compound
bleach
use
sanit
room
occupi
equip
use
patient
influenza
symptom
uncertain
reduc
public
gather
exampl
close
school
workplac
reduc
transmiss
peopl
influenza
may
move
one
area
anoth
measur
would
also
difficult
enforc
often
unpopular
small
number
peopl
infect
isol
sick
might
reduc
risk
transmiss
influenza
infect
mani
anim
speci
transfer
viral
strain
speci
occur
bird
thought
princip
anim
reservoir
influenza
virus
phylogenet
analysi
show
nucleoprotein
gene
evolv
hostspecif
lineag
includ
ii
recent
equin
strain
iii
classic
swine
swine
eg
human
strain
iv
gull
virus
v
avian
strain
includ
north
american
australian
old
world
subgroup
presenc
avian
human
nucleoprotein
swine
isol
demonstr
suscept
swine
differ
viral
strain
support
hypothesi
swine
may
serv
intermedi
introduct
avian
influenza
viru
gene
human
viru
gene
pool
strain
highli
virul
poultri
may
caus
sever
symptom
signific
mortal
avianadapt
highli
pathogen
strain
call
hpai
highli
pathogen
avian
influenza
viru
type
subtyp
caus
flu
avian
influenza
endem
mani
bird
popul
especi
southeast
asia
asian
lineag
strain
hpai
spread
global
present
evid
suggest
effici
humantohuman
transmiss
hpai
nevertheless
may
mutat
reassort
strain
capabl
effici
humantohuman
transmiss
exact
chang
requir
happen
well
understood
need
find
better
predictor
season
potenti
pandem
influenza
outbreak
pig
common
caus
sever
mortal
outbreak
influenza
viru
subtyp
occur
mexico
viru
commonli
refer
swine
flu
evid
transmiss
pig
peopl
instead
viru
spread
person
person
strain
reassort
sever
strain
usual
found
separ
human
bird
pig
parainfluenza
virus
belong
rna
paramyxoviru
famili
common
caus
respiratori
infect
children
virus
second
common
caus
lower
respiratori
tract
infect
younger
children
human
parainfluenza
virus
hpiv
second
rsv
common
caus
lower
respiratori
tract
diseas
young
children
similar
rsv
hpiv
caus
repeat
upper
respiratori
tract
infect
throughout
life
hpiv
also
caus
seriou
lower
respiratori
tract
diseas
recurr
infect
eg
pneumonia
bronchiti
bronchiol
hpiv
differ
clinic
epidemiolog
featur
distinct
clinic
featur
croup
ie
laryngotracheobronch
lead
caus
croup
children
wherea
less
frequent
detect
caus
upper
lower
respiratori
tract
ill
often
associ
bronchiol
pneumonia
infrequ
detect
possibl
less
like
caus
sever
diseas
incub
period
hpiv
gener
day
virion
unstabl
environ
surviv
hour
environment
surfac
readili
inactiv
soap
water
hpiv
spread
respiratori
secret
close
contact
infect
person
contact
contamin
surfac
object
infect
occur
infecti
materi
contact
mucou
membran
eye
mouth
nose
possibl
inhal
droplet
gener
sneez
cough
hpiv
remain
infecti
aerosol
hour
hpiv
ubiquit
infect
peopl
childhood
highest
rate
seriou
hpiv
ill
occur
among
young
children
serolog
survey
shown
children
age
year
older
antibodi
antibodi
differ
hpiv
serotyp
differ
clinic
featur
season
caus
biennial
outbreak
croup
fall
present
unit
state
oddnumb
year
caus
annual
biennial
fall
outbreak
peak
activ
occur
spring
earli
summer
month
year
viru
isol
throughout
year
infect
hpiv
confirm
either
isol
identif
viru
cell
cultur
direct
detect
viru
respiratori
secret
usual
collect
within
week
onset
symptom
use
immunofluoresc
enzym
immunoassay
pcr
assay
demonstr
signific
increas
specif
igg
antibodi
appropri
collect
pair
serum
specimen
specif
igm
antibodi
singl
serum
specimen
particular
multiplex
revers
transcriptionpcr
rtpcr
assay
use
rapid
sensit
diagnost
method
virus
accumul
knowledg
molecular
structur
mechan
replic
hpiv
acceler
research
prevent
treatment
sever
strategi
vaccin
develop
use
live
attenu
inactiv
recombin
subunit
vaccin
investig
may
becom
possibl
prevent
hpiv
infect
near
futur
nevertheless
vaccin
current
avail
protect
infect
caus
hpiv
passiv
acquir
matern
antibodi
may
play
role
protect
hpiv
type
first
month
life
highlight
import
breastfeed
strict
attent
infectioncontrol
practic
decreas
prevent
spread
infect
frequent
hand
wash
share
item
cup
glass
utensil
infect
person
decreas
spread
viru
other
exclud
children
cold
respiratori
ill
without
fever
well
enough
attend
child
care
school
set
probabl
decreas
spread
hpiv
virus
often
spread
earli
stage
ill
hospit
set
spread
hpiv
prevent
strict
attent
contact
precaut
hand
wash
wear
protect
gown
glove
rhinovirus
rv
nonenvelop
singlestrand
rna
virus
belong
picornavirida
famili
viru
frequent
associ
common
cold
rhinoviru
play
signific
role
pathogenesi
otiti
media
asthma
exacerb
current
evid
indic
viral
bacteri
infect
import
respiratori
ill
increas
sever
asthma
signific
risk
factor
develop
preschool
childhood
wheez
occurr
symptomat
rhinoviru
ill
infanc
clinic
prognost
inform
base
season
natur
rv
proven
viru
often
found
associ
increas
asthma
sever
use
sensit
rtpcr
method
respiratori
virus
found
approxim
wheez
episod
children
approxim
onehalf
episod
adult
one
studi
rv
rna
detect
asthmat
children
week
acut
exacerb
asthma
exacerb
sever
patient
persist
rv
rna
suggest
sever
acut
asthma
might
link
prolong
possibl
sever
rv
infect
case
rv
infect
mild
selflimit
despit
high
incid
preval
nasopharyng
croup
pneumonia
occasion
caus
rv
rv
transmit
aerosol
direct
contact
primari
site
inocul
nasal
mucosa
conjunctiva
may
involv
lesser
extent
rv
attach
respiratori
epithelium
spread
local
rv
effici
replic
bodi
temperatur
optim
temperatur
rv
replic
c
fact
may
explain
rv
replic
well
nasal
passag
upper
tracheobronchi
tree
less
well
lower
respiratori
tract
incub
period
approxim
day
rv
shed
larg
amount
mani
million
infecti
virion
present
per
millilit
nasal
wash
viremia
uncommon
viral
shed
occur
day
cold
symptom
recogn
patient
peak
day
ill
may
last
long
week
local
inflammatori
respons
viru
respiratori
tract
lead
nasal
discharg
nasal
congest
sneez
throat
irrit
rv
possess
variou
transmiss
mode
infect
huge
popul
given
time
aerosol
transmiss
common
transmiss
mode
respiratori
tract
infect
transmiss
occur
small
airborn
particl
inhal
larg
droplet
directli
touch
direct
hand
contact
infect
secret
indirect
contact
fomit
also
import
patient
infect
touch
nose
conjunctiva
highli
contagi
behavior
includ
nose
blow
sneez
physic
transfer
infect
secret
onto
environment
surfac
paper
tissu
contrari
popular
belief
behavior
kiss
talk
cough
even
drool
contribut
highli
spread
diseas
infect
rate
approxim
within
household
rang
within
school
indic
transmiss
requir
longterm
contact
infect
individu
brief
exposur
other
place
movi
theater
shop
mall
friend
hous
doctor
offic
incur
low
risk
transmiss
pleconaril
oral
bioavail
antivir
drug
develop
treatment
infect
caus
picornavirus
drug
act
bind
hydrophob
pocket
stabil
protein
capsid
extent
viru
releas
rna
genom
target
cell
test
volunt
clinic
trial
drug
caus
signific
decreas
mucu
secret
illnessassoci
symptom
howev
food
drug
administr
approv
drug
treatment
common
cold
gastrointestin
side
effect
insignific
coronaviru
sever
acut
respiratori
syndrom
coronaviru
genu
anim
viru
belong
famili
coronavirida
viru
envelop
positivesens
singlestrand
rna
genom
helic
symmetri
human
coronavirus
difficult
grow
laboratori
coronavirus
primarili
infect
upper
respiratori
gastrointestin
tract
mammal
bird
public
human
coronaviru
sarscov
caus
sever
acut
respiratori
syndrom
sar
uniqu
pathogenesi
caus
upper
lower
respiratori
tract
infect
also
caus
gastroenter
coronavirus
believ
caus
signific
percentag
common
cold
human
adult
primarili
winter
earli
spring
season
follow
outbreak
sar
begun
previou
year
asia
secondari
case
elsewher
world
world
health
organ
issu
press
releas
state
novel
coronaviru
identifi
sever
laboratori
caus
agent
sar
viru
offici
name
sar
coronaviru
sarscov
genom
sarscov
nucleotid
length
open
read
frame
genom
organ
similar
coronavirus
phylogenet
analys
sequenc
comparison
show
sarscov
close
relat
previous
character
coronavirus
sar
epidem
result
infect
result
death
follow
highprofil
public
sar
outbreak
renew
interest
coronavirus
mani
year
scientist
knew
exist
human
coronavirus
discoveri
sarscov
ad
anoth
human
coronaviru
list
end
independ
research
laboratori
report
discoveri
fourth
human
coronaviru
name
nl
new
coronaviru
differ
research
group
screen
clinic
specimen
individu
suffer
respiratori
ill
identifi
addit
individu
indic
viru
wide
spread
within
human
popul
adenoviru
infect
commonli
caus
ill
respiratori
system
well
variou
ill
gastroenter
conjunct
cystiti
symptom
caus
adenoviru
infect
rang
common
cold
syndrom
pneumonia
croup
bronchiti
patient
compromis
immun
system
especi
suscept
sever
complic
adenoviru
infect
adenovirus
transmit
direct
contact
fecalor
transmiss
occasion
waterborn
transmiss
type
capabl
establish
persist
asymptomat
infect
tonsil
adenoid
intestin
infect
host
shed
occur
month
year
adenoviru
infect
occur
throughout
year
outbreak
adenovirusassoci
respiratori
diseas
common
late
winter
spring
earli
summer
antigen
detect
pcr
assay
viru
isol
serolog
use
identifi
adenoviru
infect
adenoviru
excret
prolong
period
presenc
viru
necessarili
mean
associ
diseas
infect
mild
requir
either
therapi
symptomat
treatment
virusspecif
therapi
seriou
adenoviru
ill
manag
treat
symptom
complic
infect
death
rare
report
strict
attent
good
infect
control
practic
effect
stop
nosocomi
outbreak
adenovirusassoci
diseas
epidem
keratoconjunct
maintain
adequ
level
chlorin
necessari
prevent
swim
pool
associ
outbreak
adenoviru
conjunct
human
metapneumoviru
hmpv
first
isol
netherland
use
rna
arbitrarili
prime
pcr
rappcr
techniqu
identif
unknown
virus
grow
cultur
cell
serolog
studi
show
age
year
virtual
children
netherland
expos
human
metapneumoviru
viru
circul
human
least
year
hmpv
neg
singlestrand
rna
viru
famili
paramyxovirida
close
relat
avian
metapneumoviru
ampv
subgroup
c
hmpv
may
second
common
caus
rsv
lower
respiratori
infect
young
children
although
infect
hmpv
tend
occur
slightli
older
children
produc
diseas
less
sever
coinfect
virus
occur
gener
associ
wors
diseas
hmpv
shown
worldwid
circul
nearli
univers
infect
age
year
similar
influenza
rsv
activ
greatest
winter
temper
climat
avail
data
clinic
manifest
hmpv
infect
studi
children
viru
caus
upper
respiratori
tract
infect
bronchiol
pneumonia
reinfect
hmpv
occur
throughout
adult
life
hmpv
infect
document
adult
year
use
rtpcr
serolog
diagnosi
ill
gener
mild
young
adult
serolog
evid
asymptomat
infect
mani
case
human
metapneumoviru
account
approxim
respiratori
tract
infect
relat
previous
known
caus
agent
viru
seem
distribut
worldwid
season
distribut
incid
compar
influenza
virus
winter
serolog
studi
shown
age
year
virtual
children
expos
viru
reinfect
common
human
metapneumoviru
usual
caus
mild
respiratori
tract
infect
although
small
children
immunocompromis
individu
risk
sever
diseas
hospit
identif
hmpv
predominantli
reli
rtpcr
technolog
amplifi
directli
rna
extract
respiratori
specimen
treatment
symptomat
effect
treatment
vaccin
hmpv
current
avail
ribavirin
shown
effect
anim
model
aforement
virus
lead
infect
differ
part
respiratori
system
distinct
symptomatolog
part
divid
upper
airway
syndrom
lower
airway
lung
parenchyma
symptom
common
cold
upper
respiratori
tract
infect
resembl
symptom
influenza
diseas
except
usual
milder
symptom
influenza
start
abruptli
day
infect
usual
first
symptom
chill
chilli
sensat
fever
bodi
temperatur
rang
c
suzuki
colleagu
studi
natur
cours
fever
influenza
viru
infect
children
found
fever
promin
young
children
secondari
fever
observ
frequent
hour
type
durat
fever
associ
neg
age
child
posit
maxim
temperatur
symptom
influenza
may
also
includ
ach
especi
joint
throat
extrem
cold
fatigu
headach
irrit
water
eye
redden
eye
face
mouth
throat
nose
difficult
distinguish
common
cold
influenza
earli
stage
infect
flu
identifi
high
fever
sudden
onset
extrem
fatigu
subtrop
influenza
import
caus
hospit
among
children
rate
exceed
report
temper
region
influenzarel
hospit
among
children
hong
kong
influenza
virus
signific
human
respiratori
pathogen
caus
season
endem
infect
period
unpredict
pandem
worst
pandem
record
kill
approxim
million
peopl
worldwid
strike
spectrum
patholog
chang
describ
influenza
pandem
significantli
differ
histopatholog
observ
less
lethal
pandem
even
death
occur
season
influenza
outbreak
coronavirus
parainfluenza
rsv
import
virus
caus
clinic
syndrom
common
cold
virus
adenovirus
influenza
virus
caus
common
cold
like
caus
acut
nasopharyng
sever
respiratori
infect
sever
studi
demonstr
incid
common
cold
highest
preschool
elementari
schoolag
children
averag
cold
per
year
observ
age
group
even
higher
incid
children
attend
daycar
center
numer
viral
agent
involv
mani
serotyp
sever
virus
especi
rv
unusu
younger
children
new
cold
month
winter
season
adult
adolesc
typic
cold
per
year
season
increas
incid
winter
month
observ
worldwid
common
manifest
rv
common
cold
mild
selflimit
common
cold
definit
object
evid
pharyng
irrit
rv
uncommon
caus
acut
nasopharyng
howev
sever
respiratori
diseas
includ
bronchiol
asthma
exacerb
pneumonia
occur
infant
young
children
inde
rv
may
associ
sever
lower
respiratori
tract
infect
children
previous
report
particularli
noninfluenza
rsv
season
antibodi
viral
serotyp
develop
time
highest
incid
found
infant
young
children
addit
young
children
like
frequent
close
person
contact
necessari
transmit
rhinoviru
children
common
cold
usual
afebril
although
temperatur
c
may
occur
younger
children
profus
nasal
discharg
clear
wateri
mucopurul
purul
secret
common
first
day
ill
impli
bacteri
sinus
unless
symptom
sign
upper
respiratori
infect
persist
day
without
appreci
improv
despit
sore
throat
pharynx
normal
appear
without
erythema
exud
ulcer
infect
occur
rapidli
viru
adher
surfac
receptor
within
minut
enter
respiratori
tract
rv
preferenti
grow
c
oppos
bodi
temperatur
c
henc
infect
mainli
upper
respiratori
tract
influenza
caus
pneumonia
fatal
particularli
young
elderli
although
often
confus
influenzalik
viral
infect
common
cold
influenza
gener
sever
diseas
influenza
typic
transmit
airborn
aerosol
creat
cough
sneez
infect
also
occur
contact
infect
bodi
fluid
contamin
surfac
influenza
virus
inactiv
sunlight
disinfect
deterg
vaccin
influenza
avail
common
human
vaccin
trival
influenza
vaccin
tiv
contain
purifi
inactiv
materi
viral
strain
vaccin
typic
includ
materi
influenza
viru
subtyp
influenza
b
viru
strain
tiv
carri
risk
transmit
diseas
low
reactiv
vaccin
formul
year
may
ineffect
follow
year
influenza
viru
evolv
rapidli
new
strain
quickli
replac
older
one
peopl
recov
complet
week
develop
lifethreaten
complic
young
children
peopl
chronic
medic
condit
pregnant
women
risk
complic
influenza
syndrom
rare
side
effect
influenza
vaccin
incid
case
per
million
vaccin
advers
event
report
rate
reason
constant
time
new
safeti
concern
emerg
review
year
postlicensur
surveil
data
patient
flu
advis
get
plenti
rest
drink
plenti
liquid
avoid
use
alcohol
tobacco
necessari
take
medic
paracetamol
acetaminophen
reliev
fever
muscl
ach
associ
flu
children
teenag
flu
symptom
particularli
fever
avoid
take
aspirin
influenza
infect
especi
influenza
type
b
risk
rey
syndrom
antibiot
effect
infect
unless
prescrib
secondari
infect
bacteri
pneumonia
class
antivir
drug
use
influenza
neuraminidas
inhibitor
protein
inhibitor
adamantan
deriv
neuraminidas
inhibitor
current
prefer
flu
viru
infect
less
toxic
effect
antivir
drug
oseltamivir
trade
name
tamiflu
zanamivir
trade
name
relenza
neuraminidas
inhibitor
design
halt
spread
viru
bodi
drug
often
effect
influenza
b
cochran
collabor
review
drug
conclud
reduc
symptom
complic
aforement
antivir
drug
shorten
cours
influenza
diseas
approxim
day
reliev
symptom
extent
differ
strain
influenza
virus
differ
degre
resist
antivir
imposs
predict
degre
resist
futur
pandem
strain
might
increas
influenza
vaccin
among
young
children
togeth
routin
therapeut
use
neuraminidas
inhibitor
led
decreas
influenzaassoci
mortal
rate
determin
intervent
like
curtail
influenza
pandem
carrat
colleagu
grassli
colleagu
mathemat
model
transmiss
influenza
predict
viru
spread
popul
result
support
stockpil
antivir
drug
acceler
vaccin
develop
nevertheless
neuraminidas
inhibitor
use
routin
season
influenza
control
seriou
epidem
pandem
neuraminidas
inhibitor
use
public
health
measur
common
syndrom
often
affect
infant
children
younger
year
laryngotracheobronch
condit
commonli
known
croup
due
characterist
croupi
cough
associ
infect
inflammatori
subglott
region
croup
character
bark
cough
vari
degre
inspiratori
stridor
hoars
result
laryng
tracheal
obstruct
condit
may
mild
moder
sever
even
fatal
croup
often
caus
parainfluenza
viru
type
respons
major
case
howev
viral
infect
also
caus
croup
common
fall
winter
occur
yearround
slight
predilect
male
respiratori
distress
caus
inflammatori
respons
infect
rather
infect
respiratori
distress
usual
occur
young
children
airway
smaller
differ
shape
adult
make
suscept
treatment
croup
depend
sever
symptom
import
maintain
calm
atmospher
parent
child
children
manag
effect
home
antipyret
given
child
febril
adequ
hydrat
maintain
corticosteroid
mainstay
therapi
corticosteroid
potent
vasoconstrict
antiinflammatori
properti
reduc
airway
inflamm
vascular
permeabl
mucos
edema
good
evid
exist
support
use
corticosteroid
manag
sever
moder
even
mild
croup
dexamethason
often
use
due
prolong
physiolog
effect
sever
form
requir
emerg
medic
treatment
intens
care
unit
nebul
epinephrin
consid
children
moder
sever
croup
use
caution
children
tachycardia
ventricular
outlet
obstruct
racem
epinephrin
work
stimul
aadrenerg
receptor
airway
result
mucos
vasoconstrict
decreas
subglott
edema
stimul
badrenerg
receptor
result
relax
bronchial
smooth
muscl
random
studi
compar
racem
epinephrin
either
placebo
treatment
shown
signific
improv
croup
score
treat
patient
control
simultan
use
corticosteroid
help
reduc
rebound
phenomenon
associ
use
epinephrin
obviat
need
hospit
children
moder
sever
croup
blood
oxygen
satur
less
receiv
oxygen
antibiot
valu
children
moder
sever
croup
hospit
observ
intub
rare
need
lower
airway
diseas
wheezi
bronchiti
asthma
bronchiti
common
diseas
adult
popul
less
frequent
describ
children
bronchiti
usual
due
common
viral
infect
occasion
complic
secondari
bacteri
infect
jartti
colleagu
detect
metapneumoviru
pcr
consecut
children
admit
turku
hospit
finland
acut
expiratori
wheez
median
age
month
rang
month
mean
durat
hospit
stay
day
standard
deviat
mean
durat
respiratori
symptom
day
white
blood
cell
count
creactiv
protein
rant
regul
activ
normal
texpress
secret
cytokin
concentr
nasal
secret
remain
low
wherea
concentr
nasal
secret
high
human
metapneumoviru
clinic
import
caus
agent
acut
wheez
young
children
smut
colleagu
evalu
role
novel
respiratori
virus
human
metapneumoviru
hmpv
human
coronaviru
hcov
human
bocaviru
hbov
wheez
ill
children
consecut
children
present
acut
wheez
pediatr
hospit
may
novemb
prospect
studi
nasal
swab
taken
rtpcr
pcr
hmpv
hcov
hbov
posit
gene
sequenc
shell
vial
cultur
rsv
influenza
b
virus
adenoviru
parainfluenza
virus
perform
everi
fifth
sampl
two
hundr
fortytwo
nasal
swab
collect
children
median
age
month
novel
respiratori
viru
found
hmpv
hbov
hcov
found
sampl
respect
fifteen
sampl
posit
respiratori
virus
viral
coinfect
occur
virus
import
caus
wheez
preschool
children
hmpv
hcov
hbov
less
common
usual
respiratori
pathogen
term
usual
refer
acut
viral
bronchiol
infanc
temper
climat
bronchiol
frequent
seen
winter
earli
spring
tropic
countri
diseas
occur
frequent
raini
season
bronchiol
commonli
caus
rsv
human
pneumoviru
common
respiratori
virus
may
also
caus
clinic
entiti
includ
metapneumoviru
influenza
parainfluenza
coronaviru
adenoviru
rhinoviru
coryza
mild
cough
fever
lethargi
decreas
appetit
common
onset
ill
progress
noisi
raspi
breath
wheezi
cough
physic
examin
character
prolong
expiratori
phase
wheez
tachypnea
dyspnea
intercost
retract
hyperreson
chest
percuss
tachycardia
diagnosi
usual
made
clinic
examin
ambulatori
set
chest
radiographi
routin
indic
may
sometim
use
exclud
pneumonia
test
specif
viral
caus
rsv
nasopharyng
aspir
perform
test
usual
littl
effect
manag
identif
rsvposit
patient
help
diseas
surveil
patient
cohort
hospit
ward
prevent
crossinfect
reduc
need
unnecessari
diagnost
procedur
respiratori
complic
common
infant
sever
rsv
bronchiol
includ
apnea
hypoxemia
children
rsv
bronchiol
earli
life
increas
risk
develop
asthma
later
childhood
although
associ
lost
year
age
effect
specif
treatment
bronchiol
therapi
primarili
support
frequent
small
feed
encourag
maintain
hydrat
evidenc
good
urin
output
sometim
oxygen
may
requir
maintain
blood
oxygen
level
suction
nasopharynx
remov
excess
secret
often
perform
maintain
clear
airway
sever
case
nasogastr
tube
feed
intraven
fluid
requir
extrem
case
mechan
ventil
might
necessari
kellner
colleagu
perform
metaanalysi
bronchodil
therapi
infant
bronchiol
report
bronchodil
produc
modest
shortterm
improv
clinic
score
rate
durat
hospit
howev
affect
bronchodil
therapi
investig
conclud
routin
use
bronchodil
wheez
first
time
justifi
given
modest
shortterm
clinic
improv
along
high
cost
medic
theori
epinephrin
ad
advantag
b
adrenerg
select
bronchodil
aadrenerg
compon
may
diminish
catarrh
secret
mucos
edema
airway
metaanalysi
random
control
trial
includ
inhal
system
epinephrin
one
bronchodil
show
epinephrin
may
favor
salbutamol
placebo
among
outpati
bronchiol
howev
insuffici
evid
support
use
treatment
bronchiol
among
inpati
children
respond
bronchodil
bronchodil
tri
care
clinic
evalu
respons
first
dose
must
made
order
decis
made
continu
discontinu
medic
recent
multicent
doubleblind
placebocontrol
trial
includ
infant
bronchiol
seen
emerg
depart
suggest
combin
therapi
dexamethason
epinephrin
may
significantli
reduc
rate
hospit
admiss
use
ribavirin
treat
rsv
infect
controversi
ribavirin
use
sometim
infant
preexist
lung
heart
immun
diseas
american
academi
pediatr
recommend
decis
ribavirin
administr
made
base
particular
clinic
circumst
physician
experi
antibiot
usual
indic
uncompl
bronchiol
nevertheless
thorburn
colleagu
found
children
sever
rsv
bronchiol
requir
admiss
picu
infect
bacteria
lower
airway
increas
risk
bacteri
pneumonia
gener
prevent
bronchiol
reli
measur
reduc
spread
virus
caus
respiratori
infect
hand
wash
avoid
exposur
symptomat
respiratori
infect
prematur
infant
other
certain
major
cardiac
respiratori
disord
may
benefit
passiv
immun
palivizumab
monoclon
antibodi
rsv
palivizumab
administ
intramuscularli
dosag
mgkg
monthli
begin
onset
rsv
season
total
month
recommend
american
academi
pediatr
prophylaxi
highrisk
children
use
palivizumab
asian
citi
winter
definit
season
controversi
risk
factor
bronchiol
death
unit
state
describ
multipl
causeofdeath
link
birthinf
death
data
use
examin
bronchiolitisrel
infant
death
risk
factor
assess
compar
infant
die
bronchiol
surviv
infant
bronchiolitisrel
infant
death
result
averag
annual
infant
mortal
rate
per
live
birth
major
infant
death
occur
among
infant
younger
month
bronchiol
mortal
rate
highest
among
infant
weigh
less
g
birth
low
birth
weight
vlbw
compar
infant
weigh
g
low
birth
weight
lbw
g
heavier
birth
per
live
birth
respect
vlbw
lbw
infant
remain
increas
risk
die
bronchiol
control
risk
factor
risk
factor
includ
increas
birth
order
low
apgar
score
young
matern
age
unmarri
mother
tobacco
use
pregnanc
investig
conclud
vlbw
lbw
infant
increas
risk
die
bronchiol
leader
colleagu
provid
current
estim
incid
associ
risk
factor
cost
sever
rsv
infect
among
infant
unit
state
defin
emerg
depart
visit
hospit
death
emerg
depart
visit
infant
lower
respiratori
infect
diagnos
rsv
season
admit
cost
emerg
depart
visit
approxim
us
million
rsv
bronchiol
lead
caus
infant
hospit
annual
total
hospit
charg
rsvcode
primari
diagnos
year
billion
estim
rsvassoci
postneonat
death
occur
low
birth
weight
prematur
significantli
increas
rsvassoci
mortal
rate
investig
conclud
rsv
major
caus
infant
morbid
mortal
sever
rsv
highest
among
infant
black
mother
medicaidinsur
infant
prematur
low
birth
weight
significantli
increas
rsv
mortal
rate
admiss
criteria
bronchiol
deriv
base
sever
diseas
clinic
score
use
evalu
grade
bronchiol
sever
clinic
deterior
requir
picu
admiss
uncommon
occurr
previous
healthi
infant
admit
gener
pediatr
inpati
unit
rsv
infect
extrem
tachypnea
hypoxemia
associ
subsequ
deterior
howev
small
proport
patient
clinic
deterior
present
way
clinic
use
paramet
therefor
limit
adequ
oxygen
satur
maintain
avoid
hypoxia
chest
physiotherapi
use
vibrat
percuss
techniqu
reduc
length
hospit
stay
oxygen
requir
improv
sever
clinic
score
infant
acut
bronchiol
cours
rsv
diseas
variabl
east
denmark
studi
clinic
cours
milder
report
elsewher
possibl
result
low
preval
bronchopulmonari
dysplasia
denmark
howev
rsv
constitut
consider
burden
danish
pediatr
health
care
system
investig
suggest
prophylaxi
rsv
desir
sever
form
respiratori
viral
infect
rare
children
may
lead
lifethreaten
condit
sever
pneumonia
necessit
picu
admiss
occasion
result
death
communityacquir
pneumonia
cap
signific
caus
childhood
morbid
mortal
worldwid
viral
etiolog
common
young
children
cap
viral
coinfect
especi
rsv
human
bocaviru
rhinoviru
human
metapneumoviru
parainfluenza
virus
rang
children
viral
coinfect
frequent
requir
hospit
admiss
singl
viral
infect
suffic
say
viral
coinfect
frequent
children
younger
year
cap
poor
prognost
factor
although
possibl
microbi
caus
identifi
less
half
patient
clinic
find
result
blood
cultur
chest
radiograph
white
blood
cell
differenti
count
usual
distinguish
patient
defin
caus
without
known
caus
pneumonia
children
typic
bacteri
mix
bacterialvir
infect
greatest
inflamm
diseas
sever
michelow
colleagu
evalu
consecut
immunocompet
children
hospit
radiograph
confirm
lower
respiratori
infect
januari
march
one
hundr
fiftyfour
hospit
children
lower
respiratori
infect
enrol
median
age
month
rang
month
year
pathogen
identifi
children
typic
respiratori
bacteria
identifi
streptococcu
pneumonia
virus
mycoplasma
pneumonia
chlamydia
pneumonia
mix
bacterialvir
infect
multivari
logisticregress
analys
reveal
high
temperatur
c
within
hour
admiss
presenc
pleural
effus
significantli
associ
bacteri
pneumonia
oxygen
therapi
lifesav
given
oxygen
satur
less
antimicrobi
often
use
cover
possibl
coinfect
bacteria
mechan
ventil
often
requir
respiratori
failur
death
uncommon
hand
hygien
wash
soap
water
alcoholbas
hand
rub
highli
effect
reduc
influenza
viru
human
hand
appropri
hand
hygien
may
import
public
health
initi
reduc
pandem
influenza
transmiss
influenza
immun
given
children
young
month
vaccin
avail
parainfluenza
adenoviru
rhinoviru
metapneumoviru
rsv
prophylaxi
avail
expens
one
clinic
problem
face
pediatr
intensivist
differenti
viral
bacteri
infect
acut
ill
child
without
respiratori
manifest
admit
empir
cours
antibiot
often
use
initi
manag
avoid
miss
treatabl
bacteri
coinfect
low
threshold
negativepressur
revers
isol
consid
whenev
possibl
critic
ill
patient
put
risk
rapid
diagnosi
respiratori
viral
infect
children
import
prompt
diagnosi
result
significantli
reduc
hospit
stay
antibiot
use
laboratori
use
upper
airway
obstruct
croup
usual
caus
parainfluenza
viru
howev
influenza
may
common
parainfluenza
caus
croup
picu
lower
respiratori
diseas
bronchiol
pneumonia
radiograph
abnorm
often
present
render
differenti
bacteri
infect
coinfect
difficult
sometim
parenchym
involv
evidenc
abnorm
radiographi
common
rsv
influenza
infect
often
difficult
delin
viral
bacteri
infect
acut
set
initi
broadspectrum
antibiot
use
major
patient
cover
pneumonia
sepsi
antibiot
discontinu
viral
studi
posit
patient
stabil
one
studi
mortal
potenti
attribut
respiratori
virus
rsv
influenza
parainfluenza
adenoviru
low
picu
stay
adenoviru
notori
preponder
caus
sever
diseas
like
enceph
bronchiol
obliteran
myocard
seri
hon
colleagu
patient
adenoviru
die
picu
stay
three
patient
serotyp
known
abl
caus
sever
respiratori
infect
bacteri
coinfect
often
present
includ
variou
gramposit
gramneg
bacteria
cultur
tracheal
aspir
urin
blood
common
organ
streptococcu
pneumonia
extrapulmonari
manifest
viral
infect
import
caus
morbid
rang
seizur
cardiac
arrest
age
import
demograph
factor
among
respiratori
virus
rsv
infect
particular
caus
signific
morbid
mortal
young
children
chronic
lung
diseas
prematur
found
associ
infect
rsv
viru
monthli
intramuscular
inject
palivizumab
advoc
patient
vulner
rsv
infect
univers
influenza
vaccin
children
older
month
may
help
prevent
infect
influenza
recommend
unit
state
respiratori
viral
infect
lead
picu
admiss
may
lead
signific
morbid
mortal
present
pulmonari
extrapulmonari
prompt
diagnosi
ensur
appropri
treatment
corticosteroid
croup
institut
soon
possibl
vaccin
highrisk
group
may
help
prevent
infect
icu
admiss
caus
sever
childhood
respiratori
viru
infect
heterogen
infect
may
time
lifethreaten
mani
respiratori
viral
infect
share
similar
symptomatolog
occasion
caus
outbreak
sever
respiratori
diseas
mislead
abbrevi
sar
coin
diagnosi
sever
acut
respiratori
syndrom
base
clinic
definit
patient
fever
respiratori
symptom
necessarili
sever
epidemiolog
link
consid
sar
patient
clinic
diagnos
sar
may
may
sarscov
overdiagnosi
may
lead
stigmat
inconveni
workplac
school
contrast
underdiagnos
condit
may
lead
diseas
unrecogn
potenti
pathogen
spread
commun
imprecis
definit
therefor
carri
seriou
public
health
consequ
fact
clinic
featur
mani
patient
sar
neither
sever
respiratori
natur
mani
new
surveil
guidelin
confus
abbrevi
appear
new
abbrevi
ili
introduc
mean
influenzalik
ill
definit
mani
abbrevi
nearli
ident
clinic
definit
sar
ie
contact
fever
respiratori
symptomatolog
ae
symptom
caus
unnecessari
confus
inde
differ
ili
influenza
avian
flu
swine
flu
sar
viru
appli
initi
clinic
definit
sar
avian
swine
influenza
patient
sar
symptom
epidemiolog
link
like
sar
howev
term
sar
longer
use
unless
sarscov
isol
patient
regardless
whether
sever
respiratori
symptom
epidemiolog
link
present
outbreak
sever
acut
respiratori
infect
epidemiolog
link
occur
time
time
although
sarscov
may
never
come
back
sar
concept
index
surveil
epidemiolog
prognost
studi
sever
respiratori
viral
infect
stay
sar
much
aliv
among
us
